CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced results from SCD-PROTECT, a nationwide analysis of LifeVest® wearable cardioverter defibrillator (WCD) patients in Germany, presented on May 18, 2025 as a late-breaking clinical trial at the European Society of Cardiology (ESC) Heart Failure 2025 conference. Key findings across 19,598 consecutive patients:1 Despite high overall use of contemporary GDMT, i...
Read the full news release here
